CAR-T Cells Therapy for Patients With Autoimmune Diseases

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions

Autoimmune Diseases

Interventions

DRUG

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis

A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-6.0 x10\^5 CART cells/kg）

Trial Locations (1)

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV

NCT07052565 - CAR-T Cells Therapy for Patients With Autoimmune Diseases | Biotech Hunter | Biotech Hunter